Hims & Hers Stock Plunges 15%. Why Losing the Novo Wegovy Battle Is a Blow.

Core Viewpoint - Heightened regulatory scrutiny poses a significant challenge for the online drug retailer, which has recently abandoned its plans for a Wegovy copycat product [1] Group 1 - The online drug retailer is facing increased regulatory scrutiny that could impact its operations and market position [1] - The decision to shelve the Wegovy copycat plan indicates potential difficulties in navigating the regulatory landscape [1]